Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Supemtek

AstraZeneca AZ

AZ sells rare cancer drug to Sanofi

French firm’s rare disease unit Genzyme will pay $300m for the treatment

- PMLiVE

David Khougazian appointed president of Sanofi Pasteur MSD

He will succeed Dr Jean-Paul Kress atthe Sanofi Pasteur - Merck & Co venture

- PMLiVE

Amgen beats Sanofi to PCSK9 inhibitor market

EC approval for Repatha gives it a lead over Praluent

Bristol-Myers Squibb (BMS) building

BMS’ HIV combination Evotaz cleared in Europe

Comes after the firm recently announced it would shelve much of its virology unit

- PMLiVE

Brandicourt steers Sanofi onto a new heading

Unveilsmajor restructuring of the French pharma group

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

- PMLiVE

Former Sanofi UK MD to head Teva UK

Steve Oldfield has been named as the firm’s new general manager

- PMLiVE

Praluent and Repatha backed for approval in US

Sanofi and Amgen remain in fierce competition in PCSK9 inhibitors

- PMLiVE

Sanofi will resubmit Lyxumia for FDA approval in Q3

Follows the GLP-1 agonist's all-clear by ELIXA cardiovascular safety study

Sanofi reception

Sanofi and Amgen poised for cholesterol drug sales

Praluent to be assessed by FDA advisory committee later this week

- PMLiVE

Sanofi rare disease drug a breakthrough, says FDA

Regulator awarded the status to olipudase alfa for metabolic disorder

- PMLiVE

IQWiG unimpressed with Tresiba for children

German cost watchdog says Novo’s insulin may in fact cause more harm in certain patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links